detalimogene's BLA path hinges on whether 12-month CR durability data satisfy FDA's threshold for bladder-sparing approval in BCG-unresponsive NMIBC with CIS

Bull

A positive outcome would see the full 12-month CR dataset mature to a rate meaningfully above the 25% KM estimate seen in interim data — ideally in the 35-45% range or higher with tightening confidence intervals — consistent with the strong 62% 6-month CR rate observed in the post-amendment cohort. Such durability, combined with the favorable safety profile (low discontinuation and Grade 3+ TRAE rates), would satisfy FDA's threshold for a bladder-sparing indication, support a pre-BLA meeting, and underpin a compelling BLA filing that positions detalimogene as a differentiated intravesical gene therapy.

Bear

The most likely failure mode is that the 12-month CR rate remains in the 25% range or deteriorates further as more patients reach the 12-month landmark, which would call into question whether the durability bar for FDA approval is met; the already-identified signal of lower CR rates (39% at any time, 32% at 6 months) in the 32 most recently assessed patients suggests possible patient selection or assay confounding issues that could further erode the durability picture. A second failure mode is that the statistical analysis plan negotiated with FDA sets a CR durability threshold that the data cannot meet, forcing either a trial redesign or abandonment of the current BLA pathway.